Related Experiment Video
Updated: Jun 22, 2026
06:56
Development and Application of Rapamycin-regulated Tyrosine Phosphatases
Published on: September 6, 2024
Rapamycin and mTOR kinase inhibitors
1Department of Medicine, Stony Brook University, Stony Brook, NY, 11794, USA.
Journal of Chemical Biology
|July 2, 2009
Summary
Targeting the mammalian target of rapamycin (mTOR) kinase with ATP-competitive inhibitors offers a novel anticancer strategy. These inhibitors avoid resistance pathways associated with current rapamycin-based therapies, promising improved cancer treatment outcomes.
Area of Science:
- Biochemistry
- Oncology
- Pharmacology
Background:
- Mammalian target of rapamycin (mTOR) is a key regulator of cell growth, proliferation, and survival, frequently dysregulated in cancer.
- Current rapamycin-based therapies target mTOR but can activate compensatory survival pathways, potentially leading to treatment failure.
Purpose of the Study:
- To review the chemical and cellular properties of non-selective mTOR kinase inhibitors.
- To explore the potential of selective mTOR kinase inhibitors as a novel anticancer drug strategy.
Main Methods:
- Review of existing literature on mTOR signaling and inhibitors.
- Analysis of chemical structures and cellular activities of non-selective mTOR kinase inhibitors.
Main Results:
- Rapamycin analogs inhibit mTOR by binding to an allosteric site, blocking only a subset of functions.
- ATP-competitive inhibitors target the catalytic site, inhibiting all kinase-dependent mTOR functions without activating survival pathways.
Conclusions:
- Non-selective mTOR kinase inhibitors represent a promising class of anticancer agents.
- Further development of selective mTOR kinase inhibitors could lead to potent anticancer drugs with a novel mechanism of action.
Related Concept Videos
01:22PI3K/mTOR/AKT Signaling Pathway
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a rapamycin-insensitive companion...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:20The JAK-STAT Signaling Pathway
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...